SUNFLOWER(SZ:300111) Jing Ji Guan Cha Wang·2025-09-08 09:37Core Viewpoint - Company Sunflower (300111.SZ) plans to diversify by acquiring a semiconductor electronic specialty gas company, indicating a strategic shift to enhance growth opportunities amid declining performance in its core pharmaceutical business [1][2]. Company Summary - Sunflower is planning to acquire a controlling stake in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment, while also raising matching funds [1]. - The company specializes in anti-infection, cardiovascular, and digestive system drugs, and has established an integrated business model involving pharmaceutical intermediates and finished products [1]. - In April 2024, Sunflower reported a revenue of 330 million yuan, a year-on-year decrease of 2.38%, with a net profit of 6.26 million yuan, marking a return to profitability [2]. Industry Summary - The semiconductor electronic specialty gas market is experiencing significant growth, driven by the rise of the semiconductor and new energy sectors, with the market size expected to grow from 22.08 billion yuan in 2022 to 31.66 billion yuan by 2025, reflecting a compound annual growth rate of 12.8% [3]. - The demand for electronic gases is increasing due to tightening export controls in the overseas semiconductor industry, necessitating enhanced domestic production capabilities [3]. - Current market focus is on companies specializing in the research and production of electronic specialty gases, while the importance of companies with a solid industrial gas base is often overlooked [3].